HRP20210552T1 - Liječenje multiplog mijeloma (mm) - Google Patents
Liječenje multiplog mijeloma (mm) Download PDFInfo
- Publication number
- HRP20210552T1 HRP20210552T1 HRP20210552TT HRP20210552T HRP20210552T1 HR P20210552 T1 HRP20210552 T1 HR P20210552T1 HR P20210552T T HRP20210552T T HR P20210552TT HR P20210552 T HRP20210552 T HR P20210552T HR P20210552 T1 HRP20210552 T1 HR P20210552T1
- Authority
- HR
- Croatia
- Prior art keywords
- antibody
- treatment
- multiple myeloma
- use according
- administered
- Prior art date
Links
- 208000034578 Multiple myelomas Diseases 0.000 title claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 title claims 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims 2
- 229960003957 dexamethasone Drugs 0.000 claims 2
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 claims 1
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Magnetic Resonance Imaging Apparatus (AREA)
- Display Devices Of Pinball Game Machines (AREA)
Claims (4)
1. Antitijelo specifično za CD38 koje sadrži varijabilni teški lanac sekvence
QVQLVESGGGLVQPGGSLRLSCAASGFTFSSYYMNWVRQAPGKGLEWVSGISGDPSNTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDLPLVYTGFAYWGQGTLVTVSS (SEQ ID NO: 8) i varijabilni laki lanac sekvence
DIELTQPPSVSVAPGQTARISCSGDNLRHYYVYWYQQKPGQAPVLVIYGDSKRPSGIPE
RFSGSNSGNTATLTISGTQAEDEADYYCQTYTGGASLVFGGGTKLTVLGQ (SEQ ID NO: 9) i Fc regija IgG1 za uporabu u liječenju multiplog mijeloma, naznačeno time, što se navedeno antitijelo primjenjuje u dozi od 16 mg/kg ili većoj jednom tjedno (q1w) tokom najmanje osam tjedana, i pri čemu se navedeno antitijelo primjenjuje u kombinaciji sa deksametazonom.
2. Antitijelo za uporabu prema patentnom zahtjevu 1, naznačeno time, što se navedeno antitijelo primjenjuje intravenski.
3. Antitijelo za uporabu prema bilo kojem od prethodnih patentnih zahtjeva, naznačeno time, što se navedeno antitijelo primjenjuje intravenski tokom perioda od dva sata.
4. Antitijelo za uporabu prema bilo kojem od prethodnih patentnih zahtjeva, naznačeno time, što se deksametazon primjenjuje u dozi od 20 mg ili 40 mg jednom tjedno (q1W).
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15167597 | 2015-05-13 | ||
| PCT/EP2016/060810 WO2016180958A1 (en) | 2015-05-13 | 2016-05-13 | Treatment for multiple myeloma (mm) |
| EP16723349.3A EP3294769B1 (en) | 2015-05-13 | 2016-05-13 | Treatment for multiple myeloma (mm) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20210552T1 true HRP20210552T1 (hr) | 2021-05-14 |
Family
ID=53174925
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20210552TT HRP20210552T1 (hr) | 2015-05-13 | 2021-04-07 | Liječenje multiplog mijeloma (mm) |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US10533057B2 (hr) |
| EP (1) | EP3294769B1 (hr) |
| JP (2) | JP7160533B2 (hr) |
| KR (1) | KR20180008571A (hr) |
| CN (1) | CN107614530A (hr) |
| AU (1) | AU2016260895B2 (hr) |
| CA (1) | CA2984464C (hr) |
| CY (1) | CY1123982T1 (hr) |
| DK (1) | DK3294769T3 (hr) |
| ES (1) | ES2862708T3 (hr) |
| HR (1) | HRP20210552T1 (hr) |
| HU (1) | HUE054271T2 (hr) |
| IL (1) | IL255552B (hr) |
| LT (1) | LT3294769T (hr) |
| MX (1) | MX2017014396A (hr) |
| PL (1) | PL3294769T3 (hr) |
| PT (1) | PT3294769T (hr) |
| RS (1) | RS61668B1 (hr) |
| RU (1) | RU2723047C2 (hr) |
| SG (1) | SG11201708691VA (hr) |
| SI (1) | SI3294769T1 (hr) |
| WO (1) | WO2016180958A1 (hr) |
| ZA (1) | ZA201708386B (hr) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT3294769T (pt) * | 2015-05-13 | 2021-04-13 | Morphosys Ag | Tratamento para mieloma múltiplo (mm) |
| CN110144008B (zh) | 2018-02-12 | 2021-03-19 | 杭州尚健生物技术有限公司 | Cd38蛋白抗体及其应用 |
| WO2019186273A1 (en) * | 2018-03-28 | 2019-10-03 | Takeda Pharmaceutical Company Limited | Subcutaneous dosing of anti-cd38 antibodies |
| CN109265551B (zh) * | 2018-09-25 | 2020-09-15 | 华东师范大学 | Cd38抗体、嵌合抗原受体和药物 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020164788A1 (en) | 1994-12-02 | 2002-11-07 | The Wellcome Foundation Limited | Humanized antibodies to CD38 |
| JP2003524587A (ja) | 1998-06-05 | 2003-08-19 | マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチ | 多発性骨髄腫を処置するための、ｃｄ３８に対する、遺伝子操作した抗体の使用 |
| EP1174440A1 (en) | 2000-07-19 | 2002-01-23 | U-BISys B.V. | A selectively-expressed epitope on the human CD38 molecule detected by a phage display library-derived human scFv antibody fragment |
| MXPA06008700A (es) | 2004-02-06 | 2007-01-19 | Morphosys Ag | Anticuerpos anti-cd38 humanos y usos para los mismos. |
| RS54056B1 (en) | 2004-02-06 | 2015-10-30 | Morphosys Ag | ANTI-CD38 HUMAN ANTIBODIES AND THEIR USES |
| SI2567976T1 (sl) | 2005-03-23 | 2017-11-30 | Genmab A/S | Protitelesa usmerjena proti cd38 za zdravljenje multiplega mieloma |
| EP2799451A1 (en) | 2005-05-24 | 2014-11-05 | MorphoSys AG | Generation and profiling of fully human HuCAL GOLD®-derived therapeutic antibodies specific for human CD38 |
| EP3284756B1 (en) | 2005-10-12 | 2021-05-05 | MorphoSys AG | Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human cd38 |
| JP5340935B2 (ja) * | 2006-08-07 | 2013-11-13 | アッヴィ・バイオセラピューティクス・インコーポレイテッド | 抗ｃｓ１抗体に基づく組合せ療法を用いて多発性骨髄腫を処置する方法 |
| JP5476122B2 (ja) * | 2006-09-26 | 2014-04-23 | ゲンマブ エー／エス | Ｃｄ３８発現腫瘍の併用処置法 |
| EP1914242A1 (en) | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
| JP6093696B2 (ja) * | 2010-06-09 | 2017-03-08 | ゲンマブ エー／エス | ヒトｃｄ３８に対する抗体 |
| CN103118706B (zh) * | 2010-09-27 | 2016-05-18 | 莫佛塞斯公司 | 抗cd38抗体与来那度胺或硼替佐米用于治疗多发性骨髓瘤和nhl |
| WO2014089279A1 (en) * | 2012-12-05 | 2014-06-12 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Rnf41 as a biomarker predicting response to lenalidomide in non-del(5q) mds |
| CN103421115B (zh) * | 2013-09-02 | 2015-06-03 | 东南大学 | 一种cd38纳米抗体及应用 |
| TN2016000142A1 (en) * | 2013-10-31 | 2017-10-06 | Sanofi Sa | Specific anti-cd38 antibodies for treating human cancers. |
| MX2016016617A (es) | 2014-06-16 | 2017-03-23 | Mayo Foundation | Tratamiento de mielomas. |
| WO2016022589A2 (en) * | 2014-08-08 | 2016-02-11 | The Regents Of The University Of California | Methods for treating multiple myeloma |
| CR20170086A (es) | 2014-09-09 | 2017-05-22 | Janssen Biotech Inc | Terapias de combinación con anticuerpos anti-cd38 |
| PT3294769T (pt) * | 2015-05-13 | 2021-04-13 | Morphosys Ag | Tratamento para mieloma múltiplo (mm) |
-
2016
- 2016-05-13 PT PT167233493T patent/PT3294769T/pt unknown
- 2016-05-13 RS RS20210419A patent/RS61668B1/sr unknown
- 2016-05-13 CN CN201680027238.0A patent/CN107614530A/zh active Pending
- 2016-05-13 WO PCT/EP2016/060810 patent/WO2016180958A1/en active Application Filing
- 2016-05-13 DK DK16723349.3T patent/DK3294769T3/da active
- 2016-05-13 JP JP2017558542A patent/JP7160533B2/ja active Active
- 2016-05-13 ES ES16723349T patent/ES2862708T3/es active Active
- 2016-05-13 RU RU2017137496A patent/RU2723047C2/ru active
- 2016-05-13 KR KR1020177035726A patent/KR20180008571A/ko not_active Application Discontinuation
- 2016-05-13 US US15/569,495 patent/US10533057B2/en active Active
- 2016-05-13 HU HUE16723349A patent/HUE054271T2/hu unknown
- 2016-05-13 CA CA2984464A patent/CA2984464C/en active Active
- 2016-05-13 SG SG11201708691VA patent/SG11201708691VA/en unknown
- 2016-05-13 MX MX2017014396A patent/MX2017014396A/es unknown
- 2016-05-13 EP EP16723349.3A patent/EP3294769B1/en active Active
- 2016-05-13 PL PL16723349T patent/PL3294769T3/pl unknown
- 2016-05-13 AU AU2016260895A patent/AU2016260895B2/en active Active
- 2016-05-13 SI SI201631139T patent/SI3294769T1/sl unknown
- 2016-05-13 LT LTEP16723349.3T patent/LT3294769T/lt unknown
-
2017
- 2017-11-09 IL IL255552A patent/IL255552B/en unknown
- 2017-12-11 ZA ZA2017/08386A patent/ZA201708386B/en unknown
-
2019
- 2019-11-25 US US16/693,904 patent/US11591406B2/en active Active
-
2021
- 2021-03-30 CY CY20211100276T patent/CY1123982T1/el unknown
- 2021-04-07 HR HRP20210552TT patent/HRP20210552T1/hr unknown
- 2021-05-06 JP JP2021078658A patent/JP2021130668A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CY1123982T1 (el) | 2022-05-27 |
| RU2723047C2 (ru) | 2020-06-08 |
| CN107614530A (zh) | 2018-01-19 |
| MX2017014396A (es) | 2018-03-23 |
| ZA201708386B (en) | 2019-06-26 |
| PT3294769T (pt) | 2021-04-13 |
| LT3294769T (lt) | 2021-04-26 |
| US20200079871A1 (en) | 2020-03-12 |
| US11591406B2 (en) | 2023-02-28 |
| WO2016180958A1 (en) | 2016-11-17 |
| DK3294769T3 (da) | 2021-03-08 |
| PL3294769T3 (pl) | 2021-07-05 |
| IL255552A (en) | 2018-01-31 |
| IL255552B (en) | 2022-01-01 |
| RU2017137496A3 (hr) | 2019-06-13 |
| EP3294769B1 (en) | 2021-01-13 |
| KR20180008571A (ko) | 2018-01-24 |
| US20190048091A1 (en) | 2019-02-14 |
| EP3294769A1 (en) | 2018-03-21 |
| JP7160533B2 (ja) | 2022-10-25 |
| CA2984464A1 (en) | 2016-11-17 |
| ES2862708T3 (es) | 2021-10-07 |
| SG11201708691VA (en) | 2017-11-29 |
| RS61668B1 (sr) | 2021-04-29 |
| HUE054271T2 (hu) | 2021-08-30 |
| CA2984464C (en) | 2023-10-10 |
| JP2021130668A (ja) | 2021-09-09 |
| RU2017137496A (ru) | 2019-06-13 |
| US10533057B2 (en) | 2020-01-14 |
| AU2016260895A1 (en) | 2017-11-09 |
| JP2018515513A (ja) | 2018-06-14 |
| AU2016260895B2 (en) | 2021-08-05 |
| SI3294769T1 (sl) | 2021-07-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20210552T1 (hr) | Liječenje multiplog mijeloma (mm) | |
| MX2017015811A (es) | Tratamiento de cancer por bloqueo combinado de las trayectorias de señalizacion de muerte programada 1 (pd)-1 y receptor 4 de quimiocina c-x-c(cxcr4). | |
| PH12018500707A1 (en) | Anti-human cd19 antibodies with high affinity | |
| HRP20210250T1 (hr) | Učinkovita i djelotvorna kontrola serumskog fosfata za optimalno stvaranje kostiju | |
| NZ738979A (en) | Pd-1 antibodies | |
| PH12016500357A1 (en) | Diaminopyrimidine p2x3 and p2x 2/3 receptor modulators for treatment of acute, sub-acute or chronic cough | |
| EA201791675A1 (ru) | Человеческие антитела к гликопротеину вируса эбола | |
| ES2687282T3 (es) | Anticuerpos humanizados ANTI-CD134 (OX40) y sus usos | |
| PE20150002A1 (es) | Anticuerpos anti-fcrn | |
| PH12016502062A1 (en) | Compositions and methods for modulating completent factor b expression | |
| MX2022005655A (es) | Anticuerpos anti ligando de cumulo de diferenciacion 40 (cd40l) y metodos para tratar enfermedades o trastornos relacionados al ligando de cumulo de diferenciacion 40 (cd40l). | |
| IL280358A (en) | Autotactic chimeric compound and compositions for preventing, ameliorating or treating diseases by degradation of a target protein containing them | |
| SA517381991B1 (ar) | أجسام مضادة لترانس ثيرتين | |
| EA201791903A1 (ru) | β-D-2'-ДЕЗОКСИ-2'-α-ФТОР-2'-β-C-ЗАМЕЩЕННЫЕ-2-МОДИФИЦИРОВАННЫЕ-N6-ЗАМЕЩЕННЫЕ ПУРИНОВЫЕ НУКЛЕОТИДЫ ДЛЯ ЛЕЧЕНИЯ ВЫЗВАННЫХ HCV ЗАБОЛЕВАНИЙ | |
| FI3355889T3 (fi) | Diaminopyrimidiini-p2x3- ja p2x2/3-reseptorimodulaattoreita käytettäväksi yskän hoidossa | |
| HRP20192313T1 (hr) | Novo anti-netrin-1 protutijelo | |
| SA517381981B1 (ar) | أجسام مضادة لترانس ثيرتين | |
| CL2018003608A1 (es) | Anticuerpo aislado o fragmento de unión a antígeno del mismo que se une específicamente interleucina-25 hjumana (il-2525); composición farmacéutica que lo comprende; uso de dicha composición farmacéutica para tratar una enfermedad o trastorno asociado con la actividad o expresión de il-25. (divisional solicitud 201700703) | |
| MX2019009377A (es) | Anticuerpos anti-tnf, composiciones y metodos para el tratamiento de la espondilitis anquilosante activa. | |
| MX2020002406A (es) | Anticuerpo anti-epha4. | |
| MX2017012615A (es) | Anticuerpo anti-notch4 humano. | |
| PE20201171A1 (es) | Anticuerpos de cadena pesada que se unen a cd22 | |
| WO2017019540A3 (en) | Inhibitors of n-linked glycosylation and methods using same | |
| MX2021013354A (es) | Metodos para tratar y/o prevenir queratosis actinica. | |
| MX2023002994A (es) | Formas de dosificacion oral y de liberacion controlada gastrorresistentes. |